Welcome to our dedicated page for Supernus Pharma SEC filings (Ticker: SUPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing the revenue impact of Qelbree, GOCOVRI, and Trokendi XR across multiple neurology markets can bury investors in acronyms and clinical jargon. Supernus Pharmaceuticals’ SEC disclosures often exceed 250 pages and span everything from patent expirations to pivotal trial read-outs—critical data that isn’t easy to spot.
That’s why Stock Titan pairs every Supernus Pharmaceuticals SEC filing with AI-powered summaries that turn technical language into clear takeaways. Need the Supernus Pharmaceuticals annual report 10-K simplified or the latest Supernus Pharmaceuticals quarterly earnings report 10-Q filing? We surface segment sales, pipeline timelines, and royalty assumptions in seconds. Our engine flags Supernus Pharmaceuticals insider trading Form 4 transactions and pushes Supernus Pharmaceuticals Form 4 insider transactions real-time alerts the moment executives trade stock. Even sudden disclosures—see the next Supernus Pharmaceuticals 8-K material events explained—arrive on your dashboard as soon as they hit EDGAR.
Investors often ask, “Where do I find the proxy details on management pay?” One click delivers the Supernus Pharmaceuticals proxy statement executive compensation with plain-English highlights. Curious about financing terms or trial milestones? Our coverage spans every exhibit, note, and risk factor. Here’s what you can do next:
- Compare R&D spend quarter-over-quarter with Supernus Pharmaceuticals earnings report filing analysis.
- Monitor CEO and director moves via Supernus Pharmaceuticals executive stock transactions Form 4.
- Save hours by understanding Supernus Pharmaceuticals SEC documents with AI instead of line-by-line reading.
All forms—10-K, 10-Q, 8-K, S-3s, and more—update in real time, backed by expert commentary that clarifies how each disclosure may affect future CNS drug revenue. Complex biotech filings, explained simply, so you can focus on decisions, not document digging.
Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals, reported option exercise and share sales on 09/08/2025. He exercised 8,074 employee stock options with an exercise price of $25.30 per share (options vesting began 02/24/2018 and expire 02/24/2027), resulting in 8,074 common shares issued. On the same date he sold 6,322 shares at a weighted average price of $46.29 per share (sales occurred at prices between $46.00 and $46.40). Following these transactions he beneficially owned 1,111,983 common shares. The exercise and sale were made pursuant to a 10b5-1 trading plan adopted November 14, 2024.
Insider transactions by Jack A. Khattar, President and CEO of Supernus Pharmaceuticals (SUPN): On 09/05/2025 Mr. Khattar exercised 73,176 employee stock options with a $25.30 exercise price and acquired those shares. The same day he sold 55,578 shares at a weighted average price of $46.01 (sales ranged $46.00–$46.09). After these transactions he beneficially owned 1,110,231 shares directly and 1,005,600 shares indirectly through the KBT Trust. The exercise was reported under a 10b5-1 plan adopted November 14, 2024.
Supernus Pharmaceuticals insider activity notice reports a proposed sale of 6,322 common shares acquired and to be sold on 09/08/2025 following an exercise of stock options. The broker listed is Morgan Stanley Smith Barney LLC and the trade is planned on NASDAQ with an aggregate market value of $290,812. The filing also discloses multiple prior 10b5-1 sales by Jack A Khattar totaling 232,878 shares during Aug–Sep 2025, generating gross proceeds shown in the table. The filer represents no undisclosed material adverse information and certifies compliance with Rule 144 and 10b5-1 representations.
Supernus Pharmaceuticals reported an insider notice to sell common stock following an option exercise. The filer plans to sell 55,578 shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $2,524,908.54 and an approximate sale date of 09/05/2025. The shares were acquired and paid for in cash on 09/05/2025 via exercise of stock options from the issuer. The filing also discloses multiple 10b5-1 sales by Jack A Khattar in August 2025 totaling 170,300 shares with gross proceeds shown across transactions. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Insider transactions by Jack A. Khattar at Supernus Pharmaceuticals (SUPN) show option exercises and share sales completed under a 10b5-1 plan. On 08/27/2025 and 08/28/2025 Mr. Khattar acquired 17,195 and 38,779 shares by exercising employee stock options at an exercise price of $12.98 per share. He also sold 10,650 shares on 08/27/2025 at a weighted average price of $45.05 and 24,150 shares on 08/28/2025 at a weighted average price of $45.12. After these transactions his direct beneficial ownership is reported at 1,092,633 shares, with an additional 1,005,600 shares indirectly held by the KBT Trust. The Form 4 notes the 10b5-1 trading plan was adopted on November 14, 2024.
Charles W. Newhall III, a director of Supernus Pharmaceuticals, Inc. (SUPN), sold 3,588 shares of the company's common stock on 08/27/2025 under a pre-existing Rule 10b5-1 trading plan. The sales were executed at a weighted average price of $45.01 per share, with transaction prices in the range $45.00 to $45.04. After the reported dispositions, the reporting person beneficially owned 129,644 shares, reported as a direct holding. The filing includes a statement that the reporting person will provide detailed per-price sale quantities on request and notes the 10b5-1 plan was adopted March 3, 2025.
Supernus Pharmaceuticals (SUPN) Form 144 notice reports an intended sale of 24,150 common shares through Morgan Stanley Smith Barney with an aggregate market value of $1,088,440.50, based on approximately 56,073,088 shares outstanding. The filing lists the approximate sale date as 08/28/2025.
The securities were acquired and are being sold on 08/28/2025 following the exercise of stock options, with payment in cash to the issuer. The filing also discloses multiple recent Rule 10b5-1 sales by Jack A. Khattar in August 2025 totaling sizable share amounts and gross proceeds across several dates, indicating ongoing disposition of shares by this insider.
Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer at Supernus Pharmaceuticals (SUPN), reported equity transactions dated 08/25/2025. The report shows the settlement of 1,250 shares upon vesting of Performance Share Units awarded on February 23, 2023, and 581 shares were withheld by the company to satisfy tax withholding at an indicated price of $41.46 per share. Following these transactions, the reporting person beneficially owned 13,718 shares of common stock. The filing explains the PSUs vested after achievement of individual performance objectives established June 12, 2023. The form was signed by an attorney-in-fact on behalf of the reporting person on 08/27/2025.
Frank Mottola, SVP, Quality, GMP, Ops, IT at Supernus Pharmaceuticals (SUPN), reported option exercise and an immediate sale on 08/25/2025. He exercised an employee stock option with a $12.98 exercise price to acquire 14,000 shares and simultaneously sold 14,000 shares at $44.51.
After these transactions the filing shows the Reporting Person beneficially owned 29,496 shares (which includes 345 shares from the company Employee Stock Purchase Plan). The filing also notes the exercised option vests in four equal annual installments beginning March 1, 2017, and that the underlying shares were sold prior to option expiration on March 1, 2026.
Charles W. Newhall III, a director of Supernus Pharmaceuticals, Inc. (SUPN), reported the sale of 1,000 shares of the issuer's common stock on 08/25/2025 pursuant to a 10b5-1 trading plan adopted March 3, 2025. The filing shows a weighted average sale price of $45 (individual trades ranged $45.00–$45.01) and indicates the reporting person beneficially owned 133,232 shares after the transaction. The Form 4 was signed by an attorney-in-fact on 08/27/2025 and was filed as a single-person report.
FAQ
What is the current stock price of Supernus Pharma (SUPN)?
What is the market cap of Supernus Pharma (SUPN)?
